The use of a deep brain stimulation (DBS) device, also known as a brain pacemaker, can help alleviate the signs of Parkinson’s disease (PD). The device is inserted at one of the three brain sites approved by the United States Food and Drug Administration (US FDA) to block electrical signals to the brain. In the United States, the ventrointermedialis (VIM) nucleus of the thalamus, the subthalamic nucleus (STN), and the globus pallidus pars interna are the three approved brain sites for targeted stimulation (GPi). Patients who have had PD for at minimum four years, despite being medicated for motor complications, are candidates for DBS surgery.
Although Thalamotomy and Pallidotomy are also surgical options, DBS is the most popular because it does not involve destruction of the tissue and is reversible.
The forecasted growth rate for the market for DBSD (deep brain stimulation device) worldwide is 9.8 percent from its 2022 valuation of $1,188.9 Mn (2022 – 2030).
Request Here For The Sample Copy Of The Report @ https://www.coherentmarketinsights.com/insight/request-sample/84
Growth in the global market for DBSD (deep brain stimulation devices) is anticipated to be driven by the rising incidence of neurological disorders like Parkinson’s and epilepsy.
Demand for deep brain stimulation devices is predicted to rise in tandem with the rising incidence of Parkinson’s disease. For instance, the Parkinson’s disease Foundation estimates that by the year 2022, more than 10 Mn people around the world will be living with the disease. According to the group’s published research, the prevalence of Parkinson’s disease rises as people ages and affects only 4% of those under the age of 50. The annual higher incidence of Parkinson’s disease in the United States is estimated to reach 60,000 by the same source in 2021.
Need for DBS devices are predicted to rise in tandem with the rising incidence of epilepsy. For example, epilepsy is the disease of the nervous system that affects the most people worldwide, affecting about 50 Mn people as of the data released by the WHO on 9th February, 2022. The majority of people suffering from epilepsy, around 80%, reside in developing nations like India, Bangladesh, and Kenya.
The global market for DBSD (deep brain stimulation devices) is expected to expand in the coming years due to the high incidence of PD and epilepsy around the world.
The global market for DBSD (deep brain stimulation devices) is expected to expand as a result of the frequent consent and introduction of new devices.
In order to increase their product offerings, leading companies in the DBS market are focusing on getting novel devices approved and released to the public. For example, Boston Scientific Corporation released two new DBS devices in January 2019: the Vercise Gevia DBS (Deep Brain Stimulation) systems and the Vercise PC (Primary Cell).
In addition, the market’s major players are working hard to release improved versions of DBS devices that have already been approved. As an example, on 24th May,, 2022, OH-based diagnostic and therapy systems provider Great Lakes NeuroTechnologies (GLNT) announced the launch of a multicenter research study to collect data to improve its Kinesia motor assessment technology for determining whether or not a patient with Parkinson’s disease (PD) is ready to consider an advanced therapy like DBS (deep brain stimulation) or an implantable drug pump, as well as determining whether or not an existing therapy needs to be modified. When conventional treatments for motor signs such as stiffness, falls and dizziness, slowness of movement freezing, dystonia and muscle cramps have failed, this treatment is often suggested as an alternative.
Global Market for DBSD (Deep Brain Stimulation Devices)–Effect of Coronavirus (COVID-19) Pandemic
Over a hundred countries have reported cases of COVID-19 ever since the outbreak in December 2019, and on 30th January, 2020, the World Health Organization declared the situation a global public health emergency.
Due to the rapid spread of COVID-19, global activity has ceased. A greater number of people need medical attention as a result of the worldwide effort to combat this pandemic. As there was restrictions in some hospitals in the regulations and the facilities, manufacturers have had a hard time serving their surgeon customers. Measures for the lockdown limitations, for example, which could have made dealing with neurological disease and DBS management more stressful as reported in December 2020 by the National Center for Biotechnology Information. These indications are significant tiredness, low energy, and problems sleeping.
We Offer Customized Report, Click @ https://www.coherentmarketinsights.com/insight/request-customization/84
Global Market for DBSD (Deep Brain Stimulation Devices): Key Developments
- As reported in a press release from MGM Healthcare, the first Deep Brain Stimulation (DBS) surgery for Obsessive Compulsive Neurosis (OCD) was performed at MGM Healthcare in Tamil Nadu in February 2020.
- According to a report published by the Parkinson’s disease Society of the United Kingdom in 2022, the estimated rate of prevalence in 2017 was 1-2 people in every 100,000 aged 20-29 and 4 or 5 people in every 100,000 aged 30-39. This is expected to drive the growth of the global deep brain stimulation devices market. The rate of incidence increased with age, peaking at 1,696 cases per 100,000 people in the 80-84 age group, or about 1.7% of the population at this age in the United Kingdom.
- In January 2021, for example, BrainsWay Ltd., a global leader in advanced non-invasive treatment for brain disorders, declared that exclusive distribution agreement with Gaelan Medical Trade LLC, a healthcare company with extensive distribution channels in the United Arab Emirates. Under the terms of the agreement, BrainsWay will supply the Deep Transcranial Magnetic Stimulation (Deep TMS) system for the treatment of mental health conditions such as severe depression (MDD) and obsessive-compulsive disorder (OCD) throughout the United Arab Emirates over the course of several years.
Global Market for DBSD (Deep Brain Stimulation Devices): Restraints
The risks of deep brain stimulation procedures, such as lead misplacement and brain bleeding, are a major factor restraining the growth of the global deep brain stimulation device market. For instance, the implanted pulse generator is the primary driver and tunable element of DBS devices (IPG). The risk of infections caused by IPG is expected to limit the utilization of deep brain stimulation devices for Parkinson’s disease. Therefore, it is important for those in the healthcare industry to spread information about tack-up sutures, low-profile devices, antimicrobial impregnation, and co-administration.
Market leaders in DBSD (deep brain stimulation devices) include firms like Boston Scientific, Medtronic, St. Jude Medical (Abbott Laboratories), Cyberonics, Neuronetics, and Aleva Neurotherapeutics SA.
Direct Buy This Premium Research Report, Click Here @ https://www.coherentmarketinsights.com/insight/buy-now/84
Table of Content
Chapter 1 Industry Overview
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Deep Brain Stimulation Devices Market Size Analysis from 2023 to 2030
11.6 COVID-19 Outbreak: Deep Brain Stimulation Devices Industry Impact
Chapter 2 Global Deep Brain Stimulation Devices Competition by Types, Applications, and Top Regions and Countries
2.1 Global Deep Brain Stimulation Devices (Volume and Value) by Type
2.3 Global Deep Brain Stimulation Devices (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Global Deep Brain Stimulation Devices Sales, Consumption, Export, Import by Regions (2017-2023)
Chapter 5 North America Deep Brain Stimulation Devices Market Analysis
Chapter 6 East Asia Deep Brain Stimulation Devices Market Analysis
Chapter 7 Europe Deep Brain Stimulation Devices Market Analysis
Chapter 8 South Asia Deep Brain Stimulation Devices Market Analysis
Chapter 9 Southeast Asia Deep Brain Stimulation Devices Market Analysis
Chapter 10 Middle East Deep Brain Stimulation Devices Market Analysis
Chapter 11 Africa Deep Brain Stimulation Devices Market Analysis
Chapter 12 Oceania Deep Brain Stimulation Devices Market Analysis
Chapter 13 South America Deep Brain Stimulation Devices Market Analysis
Chapter 14 Company Profiles and Key Figures in Deep Brain Stimulation Devices Business
Chapter 15 Global Deep Brain Stimulation Devices Market Forecast (2023-2030)
Chapter 16 Conclusions
Explore More Related Insights:
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Coherent Market Insights Pvt Ltd,
533 Airport Boulevard, Suite 400,
Burlingame, CA 94010, United States
Phone: US +12067016702 / UK +4402081334027